.@DrRoyHerbstYale @politikaterina @MJGrantMD provide insight #ASCODailyNews on the Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer #NSCLC#lcsm@ASCO@SmilowCancer@YaleMed@YNHH https://t.co/G5HAyioPfP
Great to see our work on #HER2 mutations in #HER2 mutant #LungCancer out in print in @JTOonline.
doi: 10.1016/j.jtho.2026.103708
💡We show that there is ⬆️ clinicogenomic variability among patients with #NSCLC tumors harboring different #HER2 activating mutations. 🫁
A brief recap of our FRONT-BRAF study, retrospectively comparing immunotherapy +/- chemotherapy to BRAF+MEK inhibitors for the first-line treatment of patients with stage IV, BRAF V600E-mutated NSCLC
https://t.co/ijbh8g3iwk
@BRicciutiMD@MDAndersonNews@MSKCancerCenter
Thanks @JTOonline for the opportunity to comment on this important topic. Strong data support 🫁 screening in smokers but I don't think we are ready to expand criteria to low-risk patients without more data on their survival benefit.
More thoughts here:
https://t.co/pro7yYa8CA
In NSCLC IO trials, the moderate link between ORR & PFS and OS necessitates thorough OS analyses, even if initial PFS results are not promising. This critical measure ensures potential survival benefits are not overlooked. @lobo_goulart@harpreet_md@FDAOncology
To provide a more detailed analysis of TKIs' impact on pts w/EGFRmut #NSCLC, authors found that pts w/TP53mut/TSGmut tumors have an aggressive disease phenotype & inferior outcomes on EGFR TKIs, implying that some pts would benefit from add. therapy types. https://t.co/A1xSgmq0d5
“Approximately half of the patients who experience disease progression s/p definitive CCRT & IO per PACIFIC regimen have low-volume relapse or oligometastatic relapse & therefore are candidates for further potentially curative-intent ablative therapy.”
@IASLC@OncoAlert#lcsm
Excited to share our recent work now published in
@JTOonline:
👉Pts with #EGFR mt NSCLC with co-mut in TP53 and another suppressor gene have ⬆️aggressive dz and ⬇️outcomes on TKIs.
👉These findings may help to identify pts for Tx strategies beyond Osi.
https://t.co/oGYN4kaI4s
At #EHA2023 - Learn about the genomic evolution & resistance to a highly selective, non-covalent (reversible) BTK inhibitor in patients with CLL that were previously treated with a covalent BTK inhibitor (cBTKi). #leusm#lymsm
See the details here: https://t.co/oeF3fV7Q8x
IMscin001 (NCT03735121) was a randomized phase III trial investigating anti-PDL1 MoAb Atezolizumab as a SC formulation 💉 in NSCLC 🫁
Results of this non-inferiority study are now available #openaccess in Annals of Oncology:
https://t.co/7cwpsqdizg #lcsm
So fortunate to share our @TheLancet preprint. This is proof-of-concept showing that unanswered clinical questions in rare diseases can be accomplished by global collaboration across tens of centers! TOOK A VILLAGE to answer this and hopefully more similar efforts to come.
Hot off the press @CCR_AACR@YaleMed@YaleCancer
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations https://t.co/99x9om1qp9
Survival benefit in ADAURA: adjuvant osimertinib for resected #EGFR NSCLC hits secondary endpoint of overall survival. For those not convinced by the profound DFS benefit (HR 0.23 in stage II/IIIA), we now have OS data. @FordePatrick @DrSteveMartin
https://t.co/08uMa4GHVg
Out today in @BloodAdvances, we show stark disparities in access to end-of-life care for individuals with hematologic malignancies living in Rural America
Our findings and thoughts on this important, nuanced & policy-relevant topic below. We can do better https://t.co/n0K6XDEYCs